Table 2.
Risk factors, medications, and renal artery stenosis measures for the Cardiovascular Outcomes in Renal Artery Stenosis Trial participants by randomization group
| Measures | Stent Plus Medical Therapy, n=459 | Medical Therapy Only, n=472 | Difference [95% CI] | P Value |
|---|---|---|---|---|
| Systolic BP, mmHg | ||||
| Mean±SD (N) | 150±23 (457) | 150±23 (467) | −0.5 [−3.5 to 2.4] | 0.50 |
| Diastolic BP, mmHg | ||||
| Mean±SD (N) | 79±13 (457) | 79±13 (467) | 0.3 [−1.5 to 2.0] | 0.23 |
| Antihypertensive counts, mean±SD (N) | 2.2±1.6 (455) | 2.1±1.6 (467) | 0.1 [−0.1 to 0.3] | 0.95 |
| Antihypertensive classes, mean±SD (N) | 2.0±1.5 (455) | 2.0±1.4 (467) | 0.1 [−0.1 to 0.2] | 0.58 |
| ACE inhibitor or ARB | 83% (380/459) | 84% (397/472) | −1.3 [6.1 to 3.5] | 0.60 |
| Diuretic | 65% (298/459) | 71% (337/472) | −6.5 [−12.4 to 0.5] | 0.04 |
| Calcium channel blocker | 62% (284/459) | 65% (307/472) | −3.2 [−9.4 to 3.0] | 0.34 |
| β-Blocker | 78% (358/450) | 77% (362/472) | 1.3 [−4.1 to 6.7] | 0.64 |
| Diabetes mellitus | 32% (148/457) | 34% (162/472) | 0.1 [−0.1 to 0.3] | 0.58 |
| HbA1c, % | ||||
| Mean±SD (N) | 7.0±1.4 (132) | 6.8±1.2 (150) | 0.1 [−0.2 to 0.4] | 0.39 |
| Total cholesterol, mg/dl | ||||
| Mean±SD (N) | 164±43 (434) | 162±42 (450) | 2 [−4 to 8] | 0.50 |
| LDL cholesterol, mg/dl | ||||
| Mean±SD (N) | 92±34 (419) | 89±33 (445) | 3 [−1 to 8] | 0.15 |
| HDL cholesterol, mg/dl | ||||
| Mean±SD (N) | 43±14 (432) | 44±13 (451) | −1 [−3 to 1] | 0.23 |
| Statin use | 83% (382/459) | 87% (410/472) | −4% [−8% to 1%] | 0.12 |
| Body mass index | ||||
| Mean±SD (N) | 28.2±5.3 (458) | 28.7±5.7 (468) | −0.4 [−1.1 to 0.3] | 0.24 |
| Global ischemia | 20% (89/445) | 16% (51/315) | 4% [−2% to 9%] | 0.19 |
| Stenosis, % (core laboratory), mean±SD (N) | 67±11 (557) | 67±12 (377) | 0.96 |
P values for comparisons are generated with two–sample t tests for continuous measurements and chi-squared tests for binary measurements. HbA1c analyses include only study participants with diabetes. 95% CI, 95% confidence interval; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HbA1c, hemoglobin A1c.